Trial Profile
A study evaluating efficacy and barriers to evolocumab therapy in high risk secondary prevention patients not at LDL targets.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Nov 2017
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- 27 Nov 2017 New trial record
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association